Cherqaoui Driss - Profil du chercheur

Informations du chercheur

Nom complet

Cherqaoui Driss

Grade

PES

Spécialité

Chimie organique

Thématique de recherche

Synthèse organique et modélisation moléculaire

Laboratoire

Laboratoire de Chimie Moléculaire

Établissement

Faculté des Sciences Semlalia Marrakech

Ouvrages (0 au total)

Aucun ouvrage disponible.

Projets (2 au total)

Approches in silico, hémi-synthèse et évaluations biologiques pour le développement de nouveaux produits anticancéreux ciblant les MMPs

Type: Non spécifié

Début: 01/07/2025

Fin: 31/07/2027

Organisme financeur:

AAP « Promotion des Projets Interdisciplinaires » _ UCA

Modélisation moléculaire : Contribution à la conception d’inhibiteurs du VIH

Type: Non spécifié

Début: 01/01/2017

Fin: 30/12/2018

Organisme financeur:

Agence Universitaire de la Francophonie” and the Scientific Research Fund of Bulgaria. under project DNTS/FrPh01/1.

Publications (36 au total)

Distinguishing the optimal binding mechanism of an E3 ubiquitin ligase: Covalent versus noncovalent inhibition

Auteur: Imane Bjij, Shama Khan, Pritika Ramharak, Driss Cherqaoui, Mahmoud E. S. Soliman

Revue: Journal of Cellular Biochemistry

Année: 2019

DOI: 10.1002/jcb.28556

Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling

Auteur: Imane Bjij, Pritika Ramharack, Shama Khan, Driss Cherqaoui, Mahmoud E. S. Soliman

Revue: Molecules

Année: 2019

DOI: 10.3390/molecules24173125

In Silico SAR Studies of HIV-1 Inhibitors

Auteur: Ismail Hdoufane, Imane Bjij, Mahmoud Soliman, Alia Tadjer, Didier Villemin, Jane Bogdanov, Driss Cherqaoui

Revue: Pharmaceuticals

Année: 2018

DOI: 10.3390/ph11030069

Exploring the Structural Mechanism of Covalently Bound E3 Ubiquitin Ligase: Catalytic or Allosteric Inhibition?

Auteur: Imane Bjij, Shama Khan, Robin Betz, Driss Cherqaoui, Mahmoud E. S. Soliman

Revue: The Protein Journal

Année: 2018

DOI: 10.1007/s10930-018-9795-5

Covalent Inhibition in Drug Discovery: Filling the Void in Literature

Auteur: Imane Bjij, Fisayo A. Olotu, Clement Agoni, Emmanuel Adeniji, Shama Khan, Ahmed El Rashedy, Driss Cherqaoui, Mahmoud E.S. Soliman

Revue: Current Topics in Medicinal Chemistry

Année: 2018

DOI: 10.2174/1568026618666180731161438

Flexibility of Important HIV-1 Targets and in silico Design of anti- HIV Drugs

Auteur: Elvis A.F. Martis, Blessy Joseph, Satya P. Gupta, Evans C. Coutinho, Ismail Hdoufane, Imane Bjij, Driss Cherqaoui

Revue: Current Chemical Biology

Année: 2018

DOI: 10.2174/2212796811666170807154035

The hyperconjugation effect on the graphene counterparts based on silicon and germanium

Auteur: Hassan Chataoui, Hasna Choukri, Mohamed Maatallah, Driss Cherqaoui, Abdellah Jarid

Revue: Current Applied Physics

Année: 2017

DOI: 10.1016/j.cap.2017.06.015

Prediction of predominant configuration in enantioselective reduction of -Ketoacid derivatives with baker’s yeast using neural networks

Auteur: Didier Villemin, Driss Cherqaoui, Abdelhalim Mesbah

Revue: European Chemical Bulletin

Année: 2016

The Hyperconjugation and the Trans Bent Structure of A =A (A =C, Si,..., Pb) Double Bond, from Dimetallene A 2 H 4 to Nanosystems

Auteur: Hasna Choukri, Hassan Chataoui, Driss Cherqaoui, Abdellah Jarid

Revue: Silicon

Année: 2015

DOI: 10.1007/s12633-015-9285-8

« Précédent 2 3 4

Communications (61 au total)

Identification of novel TMPRSS4 inhibitors via homology modeling, molecular docking and molecular dynamics

Manifestation: 33rd edition of the International Congress of “Apollonia” University of Iasi

Date: 2023-03-02

Organisation: Apollonia University of Iasi, Iasi, Roumanie

8. In silico studies toward the identification of potential glycoprotein inhibitors as anti-Ebola agents

Manifestation: 33rd edition of the International Congress of “Apollonia” University of Iasi

Date: 2023-03-02

Organisation: Apollonia University of Iasi, Iasi, Roumanie

Identification of new potential HCV inhibitors

Manifestation: International bioinformatics conference (IBC 2022):Drug Design

Date: 2022-10-08

Organisation: Tanger, Maroc

In Silico approaches for the design of HCV inhibitors

Manifestation: Science week talks

Date: 2022-05-31

Organisation: Université Mohammed VI Polytechnique, Ben Guérir, Morocco

In silico QSAR-based discovery and molecular docking of novel inhibitors of the SARS-COV-2 main protease (Mpro)

Manifestation: 32nd edition of the international congress of Apollonia University "Preparing the Future by Promoting Excellence"

Date: 2022-03-02

Organisation: Iasi, Romania

QSAR Study of NS5A Inhibitors against Hepatitis C Virus using the Monte Carlo Optimization and the Genetic Algorithm Multiple Linear Regression(GA-MLR) Models

Manifestation: 6th International Conference on Computational Science and Technology 2021-ICCST

Date: 2021-10-31

Organisation: Faculty of Pharmacy, Chiang Mai University, Thailand

In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Manifestation: 6th International Conference on Computation For Sciences and Technology

Date: 2021-10-30

Organisation: Thailand

Combined singular value decomposition and linear regression methods in QSAR modelling: a case study for predicting HIV-1 and HCV biological activities

Manifestation: International Congress of &bdquo;Apollonia” University from Iași By promoting excellence, we prepare the future Edition XXXI

Date: 2021-03-01

Organisation: IAȘI, ROMANIA

Impact assessment of singular value decomposition linear regression model on QSAR modelling: A case study for predicting HIV-1 and HCV biological activities.

Manifestation: Computational Methods in Toxicology and Pharmacology Integrating Internet Resources (CMTPI-2019)

Date: 2019-06-23

Organisation: Ioannina, Greece.

« Précédent 1 2 3 4 Suivant »

Thèses (3 au total)

In Silico Drug Design of Potent SARS-CoV-2 Inhibitors

Auteur: Mehdi OUBAHMANE

Directeur: Cherqaoui Driss

Soutenance: 2023

Molecular Modeling: QSAR Studies on Reverse Transcriptase and Gp120 HIV-1 and NS4B HCV Inhibitors

Auteur: HDOUFANE Ismail

Directeur: Cherqaoui Driss

Soutenance: 2021

Targeting Protein Degradation as a Potential and Emerging Therapeutic Approach in Cancer Drug Discovery: Combinatorial In Silico Modeling to Explore the Covalent & Non-covalent Inhibition of Nedd4-1 E3 Ubiquitin Ligase

Auteur: BJIJ Imane

Directeur: Cherqaoui Driss

Soutenance: 2019

Informations du chercheur

Nom complet

Grade

Spécialité

Thématique de recherche

Laboratoire

Établissement

Ouvrages (0 au total)

Projets (2 au total)

Approches in silico, hémi-synthèse et évaluations biologiques pour le développement de nouveaux produits anticancéreux ciblant les MMPs

Mod&eacute;lisation mol&eacute;culaire : Contribution &agrave; la conception d&rsquo;inhibiteurs du VIH

Publications (36 au total)

Distinguishing the optimal binding mechanism of an E3 ubiquitin ligase: Covalent versus noncovalent inhibition

Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling

In Silico SAR Studies of HIV-1 Inhibitors

Exploring the Structural Mechanism of Covalently Bound E3 Ubiquitin Ligase: Catalytic or Allosteric Inhibition?

Covalent Inhibition in Drug Discovery: Filling the Void in Literature

Flexibility of Important HIV-1 Targets and in silico Design of anti- HIV Drugs

The hyperconjugation effect on the graphene counterparts based on silicon and germanium

Prediction of predominant configuration in enantioselective reduction of -Ketoacid derivatives with baker&rsquo;s yeast using neural networks

The Hyperconjugation and the Trans Bent Structure of A =A (A =C, Si,..., Pb) Double Bond, from Dimetallene A 2 H 4 to Nanosystems

Communications (61 au total)

Identification of novel TMPRSS4 inhibitors via homology modeling, molecular docking and molecular dynamics

8. In silico studies toward the identification of potential glycoprotein inhibitors as anti-Ebola agents

Identification of new potential HCV inhibitors

In Silico approaches for the design of HCV inhibitors

In silico QSAR-based discovery and molecular docking of novel inhibitors of the SARS-COV-2 main protease (Mpro)

QSAR Study of NS5A Inhibitors against Hepatitis C Virus using the Monte Carlo Optimization and the Genetic Algorithm Multiple Linear Regression(GA-MLR) Models

In silico identification of potent α-ketoamide inhibitors targeting the main protease of the SARS-CoV-2

Combined singular value decomposition and linear regression methods in QSAR modelling: a case study for predicting HIV-1 and HCV biological activities

Impact assessment of singular value decomposition linear regression model on QSAR modelling: A case study for predicting HIV-1 and HCV biological activities.

Thèses (3 au total)

In Silico Drug Design of Potent SARS-CoV-2 Inhibitors

Molecular Modeling: QSAR Studies on Reverse Transcriptase and Gp120 HIV-1 and NS4B HCV Inhibitors

Targeting Protein Degradation as a Potential and Emerging Therapeutic Approach in Cancer Drug Discovery: Combinatorial In Silico Modeling to Explore the Covalent &amp; Non-covalent Inhibition of Nedd4-1 E3 Ubiquitin Ligase

Modélisation moléculaire : Contribution à la conception d’inhibiteurs du VIH

Prediction of predominant configuration in enantioselective reduction of -Ketoacid derivatives with baker’s yeast using neural networks

Targeting Protein Degradation as a Potential and Emerging Therapeutic Approach in Cancer Drug Discovery: Combinatorial In Silico Modeling to Explore the Covalent & Non-covalent Inhibition of Nedd4-1 E3 Ubiquitin Ligase